Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc has received marketing authorization for its ophthalmic formulation of ONS-5010/LYTENAVA for the treatment of wet age-related macular degeneration in the European Union and the United Kingdom, highlighting the product's potential in addressing significant unmet medical needs. The company maintains a strong product pipeline, with ONS-5010 being positioned as a new ophthalmic anti-VEGF therapy that could serve as a potential first-line treatment. Analysts recognize that the approval by regulatory bodies may indicate confidence in ONS-5010's market viability and address pressing ocular health challenges, bolstering a positive outlook on the company's future performance.

Bears say

Outlook Therapeutics, Inc. faces significant challenges as its sole active development program, ONS-5010, has uncertain clinical outcomes and regulatory approval risks, especially following the missed primary endpoint in the NORSE 8 study at 8 weeks. Additionally, the company's competitive stance may weaken with the introduction of new drugs and biosimilars in the market. Financially, Outlook may require further financing to achieve profitability, raising additional concerns about its long-term viability.

OTLK has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 4 analysts, OTLK has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.